Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 5%, currently at 24.68 HKD with a trading volume of 112 million HKD, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib (赛沃替尼), will be presented at the WCLC. Savolitinib is a potent and selective oral MET tyrosine kinase inhibitor co-developed by AstraZeneca and Hutchison China MediTech [1] - The first human Phase I clinical trial data of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO annual meeting [1]
和黄医药涨超6% 将于2025年WCLC大会和CSCO年会上公布自研化合物数项研究最新数据